<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01680718</url>
  </required_header>
  <id_info>
    <org_study_id>Behavioral Neuropeptides</org_study_id>
    <nct_id>NCT01680718</nct_id>
  </id_info>
  <brief_title>Neuropeptides and Social Behavior</brief_title>
  <official_title>Neuropeptides and Social Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has long been established that interpersonal relationships can have a profound impact on&#xD;
      health and well-being. Yet, we are still learning about the complex biological processes that&#xD;
      contribute to positive social interactions and the ability to develop and maintain social&#xD;
      relationships. Recent research has begun to focus on oxytocin and vasopressin, neuropeptides&#xD;
      that are naturally produced in the hypothalamus, because administration of these&#xD;
      neuropeptides has been associated with increased trust, generosity, empathy, cooperation,&#xD;
      memory of social stimuli (e.g., faces), and brain activity in neural regions associated with&#xD;
      social and emotional processes. To date, several aspects of oxytocin and vasopressin's&#xD;
      effects on social behavior have been unexplored. As such, the overarching goal of this&#xD;
      project is to examine the effects of intranasal oxytocin and vasopressin on social working&#xD;
      memory, deception detection, sensitivity to interpersonal distance, empathy, and altruistic&#xD;
      behavior. Understanding how oxytocin and vasopressin influence these aspects of social&#xD;
      functioning will help to inform research that has begun to establish the potential for use of&#xD;
      these neuropeptides in psychiatric disorders such as autism spectrum disorders and&#xD;
      schizophrenia that are characterized by social deficits. For this study, we will recruit 150&#xD;
      healthy adults without a history of medical or psychiatric illness to come to the laboratory.&#xD;
      In the first session, participants will complete several questionnaires. In the second&#xD;
      session, participants will be randomly assigned to receive oxytocin, vasopressin, or placebo.&#xD;
      The study nurses will measure temperature, heart rate, and blood pressure (female&#xD;
      participants will also be asked to undergo a pregnancy test) before drug administration.&#xD;
      Participants will then complete computer tasks. During the second session, we will also&#xD;
      collect a saliva sample for genetic analysis and participants will be asked to complete&#xD;
      several additional questionnaires. At the end of the experimental session, participants will&#xD;
      be fully debriefed.&#xD;
&#xD;
      The investigators hypothesize that compared to placebo, oxytocin and/or vasopressin will&#xD;
      improve social working memory and deception detection, and increase empathy and altruism. It&#xD;
      is also hypothesized that main effects will not be found for oxytocin or vasopressin, but&#xD;
      rather, analyses of relevant moderators will elucidate these findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Speed in social working memory task</measure>
    <time_frame>Between 40-90 minutes post administration</time_frame>
    <description>Between group differences in the amount of time it takes to perform tasks involving social working memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of deception detection based on self-report</measure>
    <time_frame>Between 40-90 minutes post administration</time_frame>
    <description>Between group differences in deception detection accuracy based on self-reported ratings of unfamiliar others</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-reported perceptions of trust and threat</measure>
    <time_frame>Between 40-90 minutes post administration</time_frame>
    <description>Between group differences in self-reported perceptions of trust and threat towards unfamiliar faces which appear to vary in interpersonal distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-reported empathy and altruistic behavior</measure>
    <time_frame>Between 40-90 minutes post administration</time_frame>
    <description>Between group differences in self-reported empathy (empathic concern and personal distress), and altruistic behavior.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Social Psychology</condition>
  <arm_group>
    <arm_group_label>Intranasal oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal oxytocin</intervention_name>
    <description>Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).</description>
    <arm_group_label>Intranasal oxytocin</arm_group_label>
    <other_name>Syntocinon nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal vasopressin</intervention_name>
    <description>Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).</description>
    <arm_group_label>Intranasal vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal placebo</intervention_name>
    <description>Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).</description>
    <arm_group_label>Intranasal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 years of age&#xD;
&#xD;
          -  Healthy (see below)&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who gave birth in the last six months, are currently pregnant, planning to&#xD;
             become pregnant in the next 6 months, or currently breastfeeding women&#xD;
&#xD;
          -  Symptoms of runny nose due to allergies/cold or other reason&#xD;
&#xD;
          -  Current restricted fluid intake for any reason&#xD;
&#xD;
          -  Heart disease&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  History of myocardial infarction&#xD;
&#xD;
          -  History of cardiac arrhythmia&#xD;
&#xD;
          -  Kidney or liver disease&#xD;
&#xD;
          -  Vascular disease&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Migraine&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Nephritis&#xD;
&#xD;
          -  Diabetes and other endocrine diseases&#xD;
&#xD;
          -  Frequent or unexplained fainting&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  Aneurysm or brain hemorrhage&#xD;
&#xD;
          -  Active psychiatric diagnosis&#xD;
&#xD;
          -  Current psychopharmacologic treatment&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Medical or neurological illness&#xD;
&#xD;
          -  Regular use of medication (e.g., vasoconstrictive medications)&#xD;
&#xD;
          -  Medication intake less than 2 weeks prior to study (5 weeks for fluoxetine) including&#xD;
             daily non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Smoking more than 15 cigarettes a day&#xD;
&#xD;
          -  Consumption of any alcoholic beverages in the past 24 hours will be excluded&#xD;
&#xD;
          -  Elevated blood pressure (&gt;130/90)&#xD;
&#xD;
          -  Low blood pressure (&lt;90/60)&#xD;
&#xD;
          -  Body temperature &gt;100.1 F&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi I Eisenberger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Department of Psychology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2012</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Naomi Eisenberger</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>vasopressin</keyword>
  <keyword>intranasal administration</keyword>
  <keyword>healthy sample</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

